JP6990182B2 - 蝸牛および前庭細胞に核酸を送達するための材料および方法 - Google Patents

蝸牛および前庭細胞に核酸を送達するための材料および方法 Download PDF

Info

Publication number
JP6990182B2
JP6990182B2 JP2018529927A JP2018529927A JP6990182B2 JP 6990182 B2 JP6990182 B2 JP 6990182B2 JP 2018529927 A JP2018529927 A JP 2018529927A JP 2018529927 A JP2018529927 A JP 2018529927A JP 6990182 B2 JP6990182 B2 JP 6990182B2
Authority
JP
Japan
Prior art keywords
promoter
mice
cells
composition
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536420A5 (https=
JP2018536420A (ja
Inventor
スタンコヴィック，コンスタンティナ
エイチ． ヴァンデンベルゲ，ルク
ホルト，ジェフリー
ギャロック，グウェナエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2018536420A publication Critical patent/JP2018536420A/ja
Publication of JP2018536420A5 publication Critical patent/JP2018536420A5/ja
Priority to JP2021196596A priority Critical patent/JP7309827B2/ja
Application granted granted Critical
Publication of JP6990182B2 publication Critical patent/JP6990182B2/ja
Priority to JP2023110371A priority patent/JP7745594B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018529927A 2015-12-11 2016-12-12 蝸牛および前庭細胞に核酸を送達するための材料および方法 Active JP6990182B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021196596A JP7309827B2 (ja) 2015-12-11 2021-12-03 蝸牛および前庭細胞に核酸を送達するための材料および方法
JP2023110371A JP7745594B2 (ja) 2015-12-11 2023-07-05 蝸牛および前庭細胞に核酸を送達するための材料および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562266477P 2015-12-11 2015-12-11
US201562266462P 2015-12-11 2015-12-11
US62/266,462 2015-12-11
US62/266,477 2015-12-11
PCT/US2016/066225 WO2017100791A1 (en) 2015-12-11 2016-12-12 Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021196596A Division JP7309827B2 (ja) 2015-12-11 2021-12-03 蝸牛および前庭細胞に核酸を送達するための材料および方法

Publications (3)

Publication Number Publication Date
JP2018536420A JP2018536420A (ja) 2018-12-13
JP2018536420A5 JP2018536420A5 (https=) 2019-12-05
JP6990182B2 true JP6990182B2 (ja) 2022-02-15

Family

ID=59013436

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018529927A Active JP6990182B2 (ja) 2015-12-11 2016-12-12 蝸牛および前庭細胞に核酸を送達するための材料および方法
JP2021196596A Active JP7309827B2 (ja) 2015-12-11 2021-12-03 蝸牛および前庭細胞に核酸を送達するための材料および方法
JP2023110371A Active JP7745594B2 (ja) 2015-12-11 2023-07-05 蝸牛および前庭細胞に核酸を送達するための材料および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021196596A Active JP7309827B2 (ja) 2015-12-11 2021-12-03 蝸牛および前庭細胞に核酸を送達するための材料および方法
JP2023110371A Active JP7745594B2 (ja) 2015-12-11 2023-07-05 蝸牛および前庭細胞に核酸を送達するための材料および方法

Country Status (10)

Country Link
US (2) US11167042B2 (https=)
EP (2) EP3386537B1 (https=)
JP (3) JP6990182B2 (https=)
KR (1) KR102794870B1 (https=)
CN (2) CN116236591B (https=)
AU (1) AU2016366846B2 (https=)
CA (1) CA3007476A1 (https=)
ES (1) ES2903000T3 (https=)
SG (2) SG11201804814YA (https=)
WO (1) WO2017100791A1 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10834922B2 (en) * 2014-11-26 2020-11-17 Microban Products Company Surface disinfectant with residual biocidal property
SG11201804814YA (en) 2015-12-11 2018-07-30 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
JP2019530737A (ja) 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法
WO2018145111A1 (en) * 2017-02-06 2018-08-09 Children's Medical Center Corporation Materials and methods for delivering nucleic acids to cochlear and vestibular cells
US12391936B2 (en) 2017-03-17 2025-08-19 Rescue Hearing, Inc. Gene therapy systems and related methods for treatment of hearing loss
US20200248203A1 (en) * 2017-03-17 2020-08-06 Rescue Hearing Inc Gene Therapy Constructs and Methods for Treatment of Hearing Loss
AU2018261769B2 (en) 2017-05-05 2024-03-14 The Regents Of The University Of California Compositions and methods for expressing Otoferlin
US20210154326A1 (en) * 2017-06-26 2021-05-27 Arizona Board Of Regents On Behalf Of Arizona State University CRISPR-Based Synthetic Gene Circuits as Next Generation Gene Therapy of Inner Ear
EP3661523A4 (en) * 2017-08-03 2021-08-04 University of Iowa Research Foundation TREATMENT METHODS FOR GENETIC HEARING LOSS
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
DE102018100619A1 (de) 2018-01-12 2019-07-18 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Gentherapeutische Behandlung von Schwerhörigkeit
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
DE102018103924A1 (de) 2018-02-21 2019-08-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Gentherapeutische Behandlung von Schwerhörigkeit
JP7430652B2 (ja) * 2018-03-05 2024-02-13 ザ チルドレンズ メディカル センター コーポレーション 蝸牛および前庭細胞に核酸を送達するための組成物および方法
CA3094828A1 (en) 2018-03-23 2019-09-26 Massachusetts Eye And Ear Infirmary Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome
US12054724B2 (en) 2018-04-10 2024-08-06 President And Fellows Of Harvard College AAV vectors encoding clarin-1 or GJB2 and uses thereof
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN119410636A (zh) * 2018-04-27 2025-02-11 分贝治疗公司 肌球蛋白15启动子及其用途
IL278598B2 (en) 2018-05-11 2025-11-01 Massachusetts Eye & Ear Infirmary Altering tissue tropism of adeno-associated viruses
SG11202012710WA (en) * 2018-06-25 2021-01-28 Akouos Inc Methods of treating clrn1-associated hearing loss and/or vision loss
WO2020014625A1 (en) * 2018-07-13 2020-01-16 Akouos, Inc. Methods of treating non-syndromic sensorineural hearing loss
WO2020028717A1 (en) * 2018-08-01 2020-02-06 University Of Maryland, Baltimore MODULATION OF mTORC1 ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION
WO2020069320A1 (en) 2018-09-27 2020-04-02 Akouos, Inc. A method for treating an auditory neuropathy spectrum disorder
CA3115810A1 (en) * 2018-10-11 2020-04-16 Decibel Therapeutics, Inc. Aav1 vectors and uses thereof for treatment of otic indications
CA3119059A1 (en) * 2018-11-07 2020-05-14 Akouos, Inc. Compositions and methods of inducing differentiation of a hair cell
CN118497276A (zh) * 2018-11-07 2024-08-16 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
WO2020148458A1 (en) * 2019-01-18 2020-07-23 Institut Pasteur Aav-mediated gene therapy restoring the otoferlin gene
AU2020218547A1 (en) * 2019-02-08 2021-08-26 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
US20220202957A1 (en) * 2019-04-09 2022-06-30 The Regents Of The University Of California Long-lasting analgesia via targeted in vivo epigenetic repression
CN110129368B (zh) * 2019-04-22 2021-03-09 中国科学院脑科学与智能技术卓越创新中心 一种感染支持细胞和毛细胞的aav载体
US11278013B2 (en) 2019-04-26 2022-03-22 Usher 2020 Foundation Large animal model for developing therapeutic agents to treat impaired ophthalmic function in usher syndrome
EP3967706A4 (en) * 2019-05-08 2022-12-28 Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences AAV MUTANT FOR EFFICIENT INFECTION OF SUPPORT CELLS
EP3999647A1 (en) * 2019-07-18 2022-05-25 Lysogene Compositions and methods for the treatment of sanfilippo disease and other disorders
CN110423778B (zh) * 2019-07-26 2023-04-21 上海科技大学 一种逆行性重组2型腺相关病毒在感染螺旋神经元中的应用
US12570998B2 (en) 2019-09-09 2026-03-10 Massachusetts Eye & Ear Infirmary Methods and compositions for modulating the interaction between adeno-associated virus (AAV) and the AAV receptor (AAVR) for altered bio-distribution of AAV
CA3153133A1 (en) * 2019-09-30 2021-04-08 Chris Bartolome Adeno-associated virus (aav) systems for treatment of genetic hearing loss
EP4045092A1 (en) * 2019-10-18 2022-08-24 Research Institute at Nationwide Children's Hospital Gene therapy targeting cochlear cells
CA3159549A1 (en) 2019-10-30 2021-05-06 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
WO2021091950A1 (en) * 2019-11-04 2021-05-14 Decibel Therapeutics, Inc. Vestibular supporting cell promoters and uses thereof
EP4055175A4 (en) 2019-11-04 2023-11-29 Decibel Therapeutics, Inc. Cochlear inner hair cell promoters and uses thereof
WO2021108512A1 (en) * 2019-11-27 2021-06-03 Icahn School Of Medicine At Mount Sinai Gene therapy for the regeneration of auditory hair cells
US20230047254A1 (en) * 2019-12-29 2023-02-16 Gloriana Therapeutics Mammalian Cells Secreting GDNF and Their Therapeutic Use
JP7807380B2 (ja) 2020-02-21 2026-01-27 アコーオス インコーポレイテッド ヒト対象において非加齢関連聴力障害を処置するための組成物および方法
AU2021247172A1 (en) 2020-04-01 2022-09-15 University Of Florida Research Foundation, Incorporated Dual AAV-MY07A vectors with improved safety for the treatment of USH1B
WO2021222682A1 (en) * 2020-04-30 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Application of aav44.9 vector in gene therapy for the inner ear
EP4164695A4 (en) * 2020-05-13 2024-06-05 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS
EP4165194A2 (en) * 2020-05-13 2023-04-19 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
JP2023526047A (ja) * 2020-05-13 2023-06-20 アコーオス インコーポレイテッド Ｓｌｃ２６ａ４関連難聴を治療するための組成物及び方法
KR102326582B1 (ko) * 2020-05-15 2021-11-16 사회복지법인 삼성생명공익재단 청각장애의 진단용 마커 및 그의 용도
WO2022032151A1 (en) * 2020-08-07 2022-02-10 University Of Miami Treatment of sensorineural deafness
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
WO2022129543A1 (en) * 2020-12-18 2022-06-23 Institut Pasteur Gene therapy for treating usher syndrome
JP2024515629A (ja) * 2021-04-14 2024-04-10 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル ニューロフィブロミン２／マーリン（ｎｆ２）遺伝子療法のための材料及び方法
EP4334460A4 (en) * 2021-05-04 2025-11-05 Decibel Therapeutics Inc Vestibular support cells and their uses
CN113604469B (zh) * 2021-08-11 2023-01-24 复旦大学附属眼耳鼻喉科医院 基于CRISPR/CasRx的基因编辑方法及其应用
CA3233522A1 (en) * 2021-09-30 2023-04-06 Katherine Diane GRIBBLE Gene therapy delivery compositions and methods for treating hearing loss
JP2025503508A (ja) * 2021-12-23 2025-02-04 ユニバーシティ オブ ロチェスター 内耳への薬剤の送達のための組成物及び方法
US20250114480A1 (en) 2022-01-25 2025-04-10 Bridgebio Gene Therapy Research, Inc. Gene therapy for genetic hearing loss
GB202214972D0 (en) * 2022-10-11 2022-11-23 Ucl Business Ltd Products and methods for use in treating NDP-related diseases
WO2024151703A2 (en) * 2023-01-12 2024-07-18 Ohio State Innovation Foundation Gene therapy for treating hearing loss disorders
CN121311586A (zh) * 2023-05-12 2026-01-09 苏州星奥拓维生物技术有限公司 耳蜗內毛细胞特异性启动子及其应用
AU2024342045A1 (en) 2023-09-11 2026-03-26 Juntendo Educational Foundation Aav variant capable of infecting inner ear
WO2025085845A1 (en) * 2023-10-19 2025-04-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gene therapy for hearing loss and vestibular disorders
US20250276095A1 (en) 2024-03-04 2025-09-04 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
WO2026030244A1 (en) 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
WO2026050402A1 (en) 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
WO2013134022A1 (en) 2012-03-05 2013-09-12 Wake Forest University Health Sciences Regeneration of inner ear cells
WO2015054653A2 (en) 2013-10-11 2015-04-16 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
WO2015089462A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037384B2 (en) 1988-01-12 1995-12-26 Cornell Res Foundation Inc Method and apparatus for the treatment of complicated retinal detachments
US20040115621A1 (en) 2000-02-18 2004-06-17 Allen Rodrigo Ancestral viruses and vaccines
US6692526B1 (en) 2000-03-15 2004-02-17 Michael E. Snyder Ophthalmological surgery colorant and delivery system
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20050281786A1 (en) 2004-06-18 2005-12-22 David Poulsen AAV mediated gene delivery to cochlear cells
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US8388668B2 (en) 2005-08-05 2013-03-05 Gholam A. Peyman Methods to regulate polarization of excitable cells
US10751385B2 (en) * 2015-02-20 2020-08-25 Institut Pasteur Prevention and/or treatment of hearing loss or impairment
SG11201804814YA (en) 2015-12-11 2018-07-30 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
JP2019530737A (ja) * 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
WO2013134022A1 (en) 2012-03-05 2013-09-12 Wake Forest University Health Sciences Regeneration of inner ear cells
WO2015054653A2 (en) 2013-10-11 2015-04-16 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
WO2015089462A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing

Also Published As

Publication number Publication date
WO2017100791A1 (en) 2017-06-15
US20220016262A1 (en) 2022-01-20
SG10201913266UA (en) 2020-02-27
ES2903000T3 (es) 2022-03-30
JP2023145460A (ja) 2023-10-11
AU2016366846A1 (en) 2018-06-21
EP3386537A1 (en) 2018-10-17
US12102692B2 (en) 2024-10-01
SG11201804814YA (en) 2018-07-30
CN109310745B (zh) 2022-12-06
AU2016366846B2 (en) 2022-03-17
JP2022046484A (ja) 2022-03-23
CA3007476A1 (en) 2017-06-15
EP3386537A4 (en) 2019-05-15
EP3984550A1 (en) 2022-04-20
CN116236591A (zh) 2023-06-09
JP2018536420A (ja) 2018-12-13
JP7309827B2 (ja) 2023-07-18
EP3386537B1 (en) 2021-10-20
CN116236591B (zh) 2026-02-27
KR20180097631A (ko) 2018-08-31
CN109310745A (zh) 2019-02-05
US11167042B2 (en) 2021-11-09
US20180369414A1 (en) 2018-12-27
KR102794870B1 (ko) 2025-04-10
JP7745594B2 (ja) 2025-09-29

Similar Documents

Publication Publication Date Title
JP7745594B2 (ja) 蝸牛および前庭細胞に核酸を送達するための材料および方法
US20230330268A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
JP7430652B2 (ja) 蝸牛および前庭細胞に核酸を送達するための組成物および方法
Chang et al. Virally mediated Kcnq1 gene replacement therapy in the immature scala media restores hearing in a mouse model of human Jervell and Lange‐Nielsen deafness syndrome
TW202130654A (zh) 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
CA3129422A1 (en) Myosin 15 promoters and uses thereof
HK40074395A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40095383A (zh) 用於将核酸递送至耳蜗和前庭细胞的材料和方法
HK1262434B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40003977B (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
HK40003977A (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Smyrnakou-Biedenbänder Synaptic Transmission in the Inner Ear Between Basic Research and Gene Therapy
CN118591631A (zh) 硬纤毛蛋白启动子及其用途
CN121399266A (zh) 耳蜗外毛细胞特异性启动子及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211203

R150 Certificate of patent or registration of utility model

Ref document number: 6990182

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250